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Abstract 
Introduction: Multiple sclerosis (MS) is an autoimmune disease of the central nervous 
system. The exact aetiology is unknown. However, genetic and environmental factors are 
suggested to be involved in the pathogenesis of MS. Improper diet, resulting in obesity and 
metabolic syndrome, can contribute to this disease. Adipokines, secreted by adipose tissue, 
link the metabolism and immune system.  
Material and methods: We aimed to assess plasma levels of selected adipokines in newly 
diagnosed, treatment-naïve individuals with multiple sclerosis. Our group comprised 58 
individuals (31 MS patients and 27 controls, matched for age and BMI) without diabetes, 
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hypertension, or dyslipidaemia. Circulating adiponectin and all adiponectin fractions, visfatin, 
and omentin concentrations were measured. Metabolic parameters were also assessed.  
Results: In MS individuals we observed the following results: higher concentrations of 
visfatin, lower levels of omentin, and no differences in adiponectin array. There were also 
correlations between some adipokines and metabolic parameters. After adjustment to BMI, a 
statistically significant decrease in total adiponectin, high-molecular weight (HMW) 
adiponectin and omentin, and an increase in medium-molecular-weight (MMW) adiponectin 
were observed in the group of MS patients when compared to those of the controls. 
Conclusions: Our results indicate that adiponectin with its fractions, visfatin, and omentin 
cannot be considered as causative factors in the early phase of multiple sclerosis. However, 
the potential role of adipokines in MS is possible because they might be involved in the 
pathogenesis of MS, regarded as an autoimmune disorder. 
Keywords: adiponectin; adiponectin fractions; visfatin; omentin; multiple sclerosis 
 
Introduction 
Multiple sclerosis (MS) is a chronic disease of the central nervous system, which leads to 
disability. It affects over 400,000 Americans and approximately 2.3 million people worldwide 
[1]. Although the exact mechanisms leading to MS are not fully understood, it is widely 
accepted that this disease belongs to a family of autoimmune disorders [2]. Data from studies 
concerning the causes and course of this illness indicate that a disturbed immune system plays 
a causative role in the pathomechanism of MS [3]. The interaction between genetic 
predisposition and environmental factors is also necessary to initiate the disease [4]. Amongst 
the environmental factors, improper diet and obesity have been closely associated with MS 
[5]. According to the current knowledge, adipose tissue comprised of adipocytes and immune-
competent cells can produce and secrete biologically active substances, adipokines, and 
cytokines. Impaired adipose tissue function that is seen in obesity results in altered adipokine 
and cytokine profile. Consequently, disturbed adipokine and cytokine secretion lead to 
chronic low-grade inflammation. Adipokines link the metabolism and the immune system [6]. 
Adiponectin is a hormone derived mainly from the adipose tissue. It is worth noticing that 
adiponectin is downregulated in obesity [7] and is inversely correlated with BMI (body mass 
index), which serves as the simplest repeatable indicator of adipose tissue amount. Decreased 
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adiponectin levels may have an impact on the pathogenesis of insulin resistance; a negative 
correlation between adiponectin and insulin resistance index, HOMA-IR, was observed in 
subject with prediabetes [8].  
Adiponectin has anti-inflammatory, anti-atherogenic, and insulin-sensitising properties [9]. 
This adipokine exerts its action through three receptors AdipoR1, AdipoR2, and T-cadherin 
[10]. Adiponectin circulates in three main forms depending on its post-translational 
modification: low-molecular-weight (LMW) trimers, medium-molecular-weight (MMW) 
hexamers, and high-molecular-weight (HMW) multimers [11]. The biological activity differs 
between the forms. HMW adiponectin is believed to possess more potent biological effects 
than other fractions, especially on metabolic homeostasis, whereas LMW is associated with 
autoimmune processes [12, 13]. It has been found that adiponectin may influence the 
immunological system. Adiponectin possesses anti-inflammatory activity [14] – the following 
mechanisms of adiponectin action on immune cells have been reported: suppression of the 
proliferation of myelomonocytic precursor cells and the phagocytic activity of mature 
macrophages [15], regulation of tumour necrosis factor alpha (TNF-α) and interferon gamma 
(IFN-γ) production in response to antigen presentation [16], and the induction of interleukin 
10 (IL-10) and 1 (IL-1) receptor antigen (IL-1RA) in monocytes, macrophages, and dendritic 
cells (DC) [3, 6]. Furthermore, adiponectin acts on endothelial cells by inhibiting the 
expression of TNFα-induced adhesion molecules, such as vascular cell adhesion molecule 1 
(VCAM-1), endothelial-leukocyte adhesion molecule 1 (E-selectin), and intracellular 
adhesion molecule 1 (ICAM-1). The result of this particular adiponectin activity includes 
reduced monocyte adhesion to endothelial cells [6, 14]. 
Interestingly, in human monocytic cells, HMW adiponectin has been shown to induce IL-6 
production and secretion, while LMW acted as an anti-inflammatory factor because it reduced 
the production of IL-6 and inhibition of IL-10 synthesis [17]. Therefore, adiponectin, 
dependent on the isoform, may have pro- or anti-inflammatory activity. Furthermore, 
adiponectin release could be modulated during inflammation becasue TNF-α impairs 
adiponectin multimerisation and decreases its secretion [18]. 
Visfatin, named also pre-B-cell colony-enhancing factor, is predominantly secreted by 
macrophages of visceral adipose tissue. Visfatin is induced by peroxisome proliferator-
activated receptor gamma in macrophages, mostly M1 subtype localised in adipose tissue, but 
not in adipocytes [19, 20]. The level of visfatin increases significantly in obesity [21]. It acts 
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as a potent modulator of inflammation with dual pro- and anti-inflammatory activity. Visfatin 
may upregulate the secretion of TNF-α, IL-1β, and IL-6 as well as IL-4, IL-10, and IL-1Ra 
[20]. It promotes activation of T cells by enhancing the expression of co-stimulatory 
molecules, including CD40, CD54, and CD80, on monocytes [6]. Visfatin acts as a 
chemotactic factor on monocytes and lymphocytes. Visfatin possesses also the ability to 
increase levels of selected cell adhesion molecules ICAM-1, VCAM-1, and E-selectin in 
endothelial cells [22]. Also, visfatin affects the development of B and T cells [22].  
Omentin is predominantly produced by the stromal-vascular fraction of visceral adipose 
tissue, but not by mature adipocytes. Interestingly, only very small amounts of omentin are 
produced by subcutaneous adipose tissue [23]. Production of omentin remains under glucose 
and insulin regulation [24]. It has been suggested that omentin plays a role in metabolic 
diseases, bone metabolism, inflammatory diseases, and others. Moreover, an association 
between decreased omentin levels and these diseases has been observed. However, enhanced 
omentin concentration was related to the acute phase after the onset of these diseases [25]. 
In reference to existing data concerning the potential role of adipokines in inflammatory 
processes and our experience in assessment of adipokines in Alzheimer’s disease, a disease 
caused both by neurodegeneration and local inflammation [26], we aimed to assess the levels 
of selected adipokines in newly diagnosed, naïve-to-treatment patients with multiple sclerosis. 
Also, in our study sample, some individuals presented overweight or obesity but no other 
metabolic abnormalities (needed to treat dyslipidaemia, diabetes mellitus, hypertension).  
 
Material and methods 
Subjects 
The study included 31 individuals (21 women and 10 men) with newly diagnosed multiple 
sclerosis, aged between 19 and 48 years (median: 33 years), and 27 subjects (23 women and 
four men) from the control group, aged between 27 and 40 years (median: 33 years). The 
controls were recruited from patients with tension headaches. The whole group under the 
study was hospitalised once in a single centre, the Department of Neurology of the Medical 
University of Warsaw (Bielanski Hospital Warsaw, Poland).  
All study participants underwent the same diagnostic procedures: medical examination, brain 
magnetic resonance imaging (MRI) scan with gadolinium contrast, and cerebrospinal fluid 
5 
 
examination performed to confirm or exclude the presence of oligoclonal bands and to 
determine the cerebrospinal (CSF) immunoglobulin (IgG) index.  
Diagnosis of MS was established according to the Diagnostic Criteria for Multiple Sclerosis 
(2010 Revisions to the “McDonald Criteria”) [27]. The severity of neurological symptoms of 
MS was evaluated using the Expanded Disability Status Scale (EDSS). Based on the medical 
history and records, the time from the first symptoms of MS to the disease diagnosis was from 
one to six months. At the time of hospitalisation, all MS patients had clinical manifestations 
of the disease (with disease relapse). MS individuals were naïve to any MS treatment.  
To avoid potential confounding factors in adipokine assessment, we carefully selected study 
participants and excluded all subjects with diabetes mellitus, hypertension, and dyslipidaemia 
as well as those treated with anti-hypertensive, anti-diabetic, and cholesterol-lowering 
medications. Exclusion criteria included also heart failure, liver and kidney failure, active 
cancer, or history of cancer disease, diabetes insipidus, mental illness, endocrine disorders, 
and any type of corticosteroid treatment within the last three months. Smokers and alcohol 
drinkers were not selected to participate in the study.  
The study protocol was accepted by the Ethical Commission of the Centre of Postgraduate 
Medical Education, Warsaw. The study was conducted in accordance with the principles of 
the Helsinki II Declaration. Signed consent was obtained from all participants. 
 
Anthropometric measurements   
Anthropometric measurements were carried out in each patient to assess the body mass index 
(BMI). BMI was calculated according to the standard formula: weight / height2 [kg/m2]. 
 
Analytical methods 
Blood samples were taken after at least six hours of fasting. Blood was collected in tubes 
containing EDTA. The plasma was separated by centrifuged at 1200 g for 10 minutes at 4°C 
and immediately stored at −70°C until further peptide analyses. Biochemical parameters, 
including fasting plasma glucose levels, and lipid profiles were estimated using routine 
laboratory tests. Insulin resistance was calculated from the fasting plasma insulin and glucose 
values using the homeostasis model assessment of insulin resistance (HOMA-IR) formula: 
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fasting plasma glucose [mmol/L]  fasting plasma insulin concentration [µIU/mL]/22.5. 
Insulin resistance was defined as HOMA-IR > 2.5. 
 
Hormone assays 
Plasma total adiponectin and HMW, MMW, and LMW adiponectin concentrations were 
measured using a commercial enzyme-linked immunosorbent assay kit (ELISA) according to 
the manufacturer's protocol (ALPCO Diagnostics, Windham, NH, USA). The sensitivity of 
the assay was 0.019 ng/mL. The intra-assay coefficient of variation (CV) was 5.4% for total 
adiponectin, 5.0% for HMW adiponectin and MMW + HMW adiponectin, while the inter-
assay CV was 5.0% for total adiponectin, 5.7% for HMW adiponectin, and 6.0% for MMW + 
HMW adiponectin.  
Plasma omentin concentration was measured by ELISA kit according to the manufacturer's 
protocol (BioVendor Laboratory Medicine, Brno, Czech Republic). The sensitivity of the 
assay was 0.5 ng/mL. The intra-assay and inter-assay CV were less than 5%. 
Plasma visfatin concentration was measured by an enzyme immunoassay kit (EIA) according 
to the manufacturer's protocol (Phoenix Pharmaceuticals Inc., Burlingame, CA, USA). The 
sensitivity value for visfatin was 2.68 ng/mL. The intra-assay and inter-assay CV were less 
than 10% and 15%, respectively.  
Plasma insulin concentrations were determined using immunoradiometric assay (DIA Source 
Immunoassay SA, Nivelles, Belgium). The detection limit was 1 μIU/mL. Intra- and inter-
assay coefficients of variation were 2.1% and 6.5%, respectively. 
 
Statistical analysis  
Statistical analysis was conducted using Statistica 12 (StatSoft Inc., USA). Data are given as 
median and interquartile range (IQ range). The normality of distribution was estimated using 
the Shapiro-Wilk test. Results were compared between MS and control groups by Mann-
Whitney U test. The coefficient correlation between tested adipokines and anthropometric as 
well as metabolic parameters was applied with the use of the Spearman test. All adipokines 
were adjusted to BMI. The values < 0.05 were considered as statistically significant.  
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Results  
Clinical and anthropometric data, as well as biochemical results of patients diagnosed with 
multiple sclerosis and the control group, are presented in Table 1.  
There were no statistically significant differences between the examined groups in terms of 
age, BMI, total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglycerides. In the group 
of patients with MS, significantly higher insulin values were found (medians: 14 µIU/mL vs. 
9 µIU/mL; p < 0.05), while HOMA-IR showed a tendency for higher values (medians: 3.27 
vs. 2.16; p = 0.08). 
The analysis showed an increased concentration of visfatin and decreased values of omentin 
in patients with newly diagnosed MS in comparison to the results of the controls (medians: 
9.64 ng/mL vs. 8.76 ng/mL; p < 0.05 and 240.91 ng/mL vs. 313.59 ng/mL; p < 0.05, 
respectively). There were no statistically significant differences between the studied groups 
when adiponectin and all its fraction concentrations were compared.  
To exclude the influence of adiposity measured with BMI in the evaluation of the adipokines, 
we adjusted the adipokine levels to the BMI. After adjustment, a statistically significant 
decrease in total adiponectin (medians: 4.5 µg/mL vs. 5.65 µg/mL; p < 0.001), HMW 
adiponectin (medians: 2.4 µg/mL vs. 2.74 µg/mL; p < 0.001), as well as omentin (medians: 
240.91 ng/mL vs. 313.59 ng/mL; p < 0.05) and an increase in MMW adiponectin (medians: 
1.22 µg/mL vs. 1.04 µg/mL; p < 0.001) were observed in the group of MS patients when 
compared to those of the controls. There were no statistically significant differences in LMW 
levels of adiponectin before and after adjustment to BMI. Moreover, after adjustment to BMI, 
differences in visfatin levels became non-significant. 
Data concerning adipokines are presented in Table 2. 
Correlations of adiponectin and its fractions with other parameters are presented in Table 3.  
In detail, as could be expected, positive correlations of total adiponectin and HMW 
adiponectin with HDL-cholesterol (R = 0.64; p < 0.001 and R = 0.61; p < 0.001, respectively) 
and negative with BMI (R= –0.60; p < 0.001 and R = –0.53; p < 0.001, respectively) LDL-
cholesterol (R = –0.42; p < 0.05 and R = –0.40; p < 0.05, respectively), insulin (R = –0.48; p 
< 0.01 and R = –0.54; p < 0.01, respectively), and HOMA-IR (R = –0.47; p < 0.01 and R = –
0.53; p < 0.001, respectively) were found. Medium molecular-weight adiponectin correlated 
positively with HDL-cholesterol (R = 0.55; p < 0.01) and negatively with BMI (R = –0.58; p 
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< 0.001) and triglycerides (R = –0.40; p < 0.05). Low molecular-weight adiponectin showed 
negative correlation with BMI (R = –0.36; p < 0.05) and LDL-cholesterol (R = –0.41; p < 
0.05) and positive with HDL-cholesterol (R = 0.45; p < 0.05). 
The assessment of the relationship between omentin and the anthropometric parameters as 
well as biochemical results demonstrated a negative correlation between omentin and insulin 
(R = –0.47; p < 0.01) and HOMA-IR (R = –0.43; p < 0.05).  The results of the tests are shown 
in Table 4. 
There was no statistically significant correlation for visfatin. 
The correlation between adipokines and biochemical and anthropometric parameters and the 
degree of disability evaluated by the EDSS scale was also assessed, showing that EDSS 
correlated positively with BMI (R = 0.36; p < 0.05) and negatively with HDL-cholesterol (R 
= –0.47; p < 0.01) (Tab. 5). 
 
Discussion 
Our study is the first in which a full spectrum of adiponectin was assessed in patients 
diagnosed with multiple sclerosis. We found no significant differences between adiponectin 
and the levels of its fractions when the MS group and the controls were compared. However, 
when the adjustment to BMI as a confounding factor was performed, marked differences were 
observed, with lower levels of total and HMW adiponectin and higher values of MMW 
adiponectin in MS. The significance of our findings is that changes in the adiponectin array 
may depend on factors other than BMI only. 
Data in the literature concerning adiponectin concentration (without adjustment to BMI) in 
individuals suffering from multiple sclerosis are inconsistent. 
In line with our non-adjusted to BMI results, Hietaharu et al. failed to find significant 
differences between adiponectin concentration in serum of MS patients and the controls, who, 
interestingly, were twins. Of note, the twins with MS had higher concentrations of 
adiponectin in CSF than their asymptomatic co-twins [28]. These findings suggest that 
peripheral secretion of adiponectin does not mirror the production in the central nervous 
system. As in our results, adiponectin in newly diagnosed MS patients did not vary in 
comparison with the healthy controls in the study by Penesova et al. [29]. 
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Contrary to our findings, the group of Signoriello found that total adiponectin was markedly 
higher in patients with MS when compared with controls. Furthermore, the authors suggested 
that the adiponectin oligomerisation is altered in MS because they observed an increase in 
HMW oligomers. Notably, the results of longitudinal observation suggest that patients with 
MS with higher levels of adiponectin at baseline have a significantly higher risk of 
progression and severity [30]. Furthermore, the group of Palavra observed an increased 
adiponectin concentration in their group of individuals suffering from MS [31].  
Düzel et al. also found higher adiponectin levels in MS than in the controls. Interestingly, 
there were differences in adiponectin concentration amongst MS patients with a different first 
clinical episode. As reported, serum adiponectin levels were found to be significantly lower in 
patients presenting with optic neuritis in the first clinical episode than in other MS 
individuals, and the results in patients with optic neuritis were comparable to those of the 
controls [32]. 
Interestingly, Kraszula et al. in one study and Musabak et al. in another study reported that 
they independently observed in MS individuals a lower concentration of adiponectin than in 
the sera of controls [33, 34]. However, it should be highlighted that both groups of patients 
were already treated for MS in the time of the study. Furthermore, results from Yousefian et 
al. showed a lower concentration of adiponectin in MS patients compared to the controls with 
concomitant differences in single nucleotide polymorphism of the adiponectin gene, which 
additionally was gender specific. Besides, adiponectin genotype was also associated with 
susceptibility to a specific type of MS, primary progressive multiple sclerosis [35].  
So far only a few authors have presented their results concerning adiponectin in MS after 
adjustment to BMI. Contrary to our data, Çoban et al. found higher total adiponectin 
concentration among MS individuals. These authors suggested the involvement of adiponectin 
as well as other adipokines in the pathogenesis and progression of MS [36]. It should also be 
noted that results from a prospective study by the group of Kvistad indicate that serum levels 
of adiponectin, also adjusted for BMI, are not associated with multiple sclerosis disease 
activity or treatment response [37]. It is noteworthy that results of a Mendelian randomisation 
study suggested that lifelong exposure to a substantially (two-SD) genetically elevated 
adiponectin level has no clinically relevant effects on MS susceptibility in individuals of 
European descent [38]. 
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The explanation for the adiponectin levels differences between published results may include 
influence on the results by sample size, age, race, the presence of metabolic alterations (e.g. 
diabetes), MS duration, MS type, and treatment.  
An important role of adiponectin in MS has been confirmed in an experimental study by 
Piccio et al. The authors performed their study on adiponectin knock-out (ADPKO) mice with 
experimental autoimmune encephalomyelitis (EAE). ADPKO mice had a worse EAE course 
with higher central nervous system (CNS) inflammation, demyelination, and axonal injury 
than wild-type (WT) mice. In vitro measurement of proliferation and cytokine from 
immunised ADPKO vs. WT mice in response to antigen revealed that pro-inflammatory 
cytokines (IFNγ TNFα, IL-17, and IL-6) were higher in ADPKO compared to WT mice. 
Furthermore, the spleen and central nervous system of ADPKO had fewer T regulatory cells 
(Tregs) than those of WT mice. Noticeably, globular adiponectin (gADP) administration in 
vivo ameliorated EAE and was associated with an increase in Tregs. These results confirm 
that adiponectin is a potent regulator of T-cell functions during EAE [39]. 
Another in vitro study by Zhang et al. also indicated that adiponectin deficiency promoted 
CNS inflammation and demyelination and exacerbated experimental EAE. Detailed data 
showed that adiponectin deficiency increased the Th1 and Th17 cell cytokines of both the 
peripheral immune system and CNS in mice suffering from EAE, and predominantly 
promoted the antigen-specific Th17 cells’ response in autoimmune encephalomyelitis. These 
results suggest that adiponectin could inhibit Th17 cell-mediated autoimmune CNS 
inflammation [40]. 
In our MS group, we found significantly higher levels of visfatin when compared to the 
controls. However, the difference diminished after adjustment to BMI.  
Our non-adjusted-to-BMI results are in concordance with the findings of Emamgholipour et 
al., who observed elevated visfatin levels in patients with MS. In addition, these authors found 
a positive correlation of visfatin with TNF-α, IL-1β, and high-sensitivity C-reaction protein 
(hs-CRP) in the group diagnosed with MS [41]. Moreover, in the study by Mirzaei et al. the 
levels of visfatin were also significantly higher in MS patients [42]. Both groups reported data 
that were not adjusted to BMI.  
To our best knowledge, there is only one study in which omentin was assessed in individuals 
suffering from multiple sclerosis. The group of Assadi failed to find a significant difference in 
the levels of omentin after adjustment to BMI between MS subjects and their healthy 
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counterparts [43]. Our results showed a marked difference when two groups were compared 
both before and after adjustment to BMI. We also observed in our MS group a negative 
correlation between omentin and insulin levels and the insulin resistance indicator HOMA-IR.  
We are aware of the limitations of our study. Firstly, we could point out the relatively small 
sample size. However, we carefully selected study participants to achieve a homogenous 
group without the occurrence of metabolic disturbances, which included diabetes, 
hypertension, and dyslipidaemia in need of treatment. Also, our group of multiple sclerosis 
patients was unique due to an early and active phase of the disease, and because they were 
naïve to any treatment. 
Secondly, we assessed only selected adipokines, but we choose those that were not yet well 
studied.  
To conclude, our results indicate that adiponectin with its fractions, visfatin, and omentin 
cannot be considered as causative factors in the early phase of multiple sclerosis. However, 
based on our findings and data from other authors, a potential role of adipokines in MS is 
possible because they might be involved in the pathogenesis of MS regarded as an 
autoimmune disorder. 
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Table 1. Patients’ demographic and clinical parameters 
 MS group 
(n = 31) 
Control group 
(n = 27) 
p 
Age (years) 33 
(29–39) 
33 
(27–40) 
NS 
BMI [kg/m2] 22.8 
(20.9–26.2) 
24.46 
(21.97 -27.14) 
NS 
EDSS 1.5 
(1–2) 
– – 
Total cholesterol  
[mg/dL] 
182.5 
(163.3–205.1) 
177.23 
(152–199.8) 
NS 
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HDL-cholesterol  
[mg/dL] 
62.5 
(46.3–74.5) 
55.00 
(45.9–71.2) 
NS 
LDL-cholesterol  
[mg/dL] 
103.4 
(81.7–126) 
99.8 
(76.80–121.7) 
NS 
Triglycerides  
[mg/dL] 
77.9 
(56.4–120) 
88.76 
(57.7–125.9) 
NS 
Glucose  
[mg/dL] 
90.0 
(83.6–97) 
92.8 
(85.3–99.0) 
NS 
Insulin [µIU/mL]  14 
(9.8–23.5) 
9 
(8.4–12.5) 
< 0.05 
HOMA-IR 3.27 
(2.12–5.28) 
2.16 
(1.8– 3.7) 
0.08 
Data are given as a median and interquartile range (IQ range). MS — multiple sclerosis; BMI — body 
mass index; EDSS — Expanded Disability Status Scale; HDL — high-density lipoproteins; LDL — 
low-density lipoproteins; HOMA-IR — Homeostatic Model Assessment-Insulin Resistance; NS — 
non-significant 
 
Table 2. Assessment of adipokines in patients with multiple sclerosis (MS) and the controls 
 MS group 
(n = 31) 
Control 
group 
(n = 27) 
p p adjusted to 
BMI 
Total adiponectin 
[ug/mL] 
4.5 
(2.9–7.6) 
5.65 
(4.3–6.1) 
NS < 0.001 
HMW adiponectin 
[ug/mL] 
2.4 
(1.2–3.5) 
2.74 
(2.0–3.5) 
NS < 0.001 
MMW adiponectin 
[ug/mL] 
1.22 
(0.8–1.9) 
1.03 
(0.6–1.6) 
NS < 0.001 
LMW adiponectin 
[ug/mL] 
1.15 
(0.7–1.7) 
1.41 
(1.2–1.8) 
NS NS 
Visfatin [ng/mL] 9.64 
(7.8–12.0) 
8.76 
(5.3–10.3) 
< 0.05 NS 
Omentin [ng/mL]  240.91 
(152–381) 
313.59 
(263–434) 
< 0.05 < 0.05 
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Data are given as a median and interquartile range (IQ range). MS — multiple sclerosis; HMW — 
high molecular weight; MMW — medium molecular weight; LMW — low molecular weight; BMI — 
body mass index; NS — non-significant 
 
Table 3. Correlations of adiponectin and its fractions in patients with multiple sclerosis (MS) 
Parameter A Parameter B R p 
Total adiponectin BMI –0.60 < 0.001 
Total adiponectin HDL-cholesterol 0.64 < 0.001 
Total adiponectin LDL-cholesterol –0.42 <0.05 
Total adiponectin Insulin –0.48 < 0.01 
Total adiponectin HOMA-IR –0.47 < 0.01 
HMW adiponectin BMI –0.53 < 0.001 
HMW adiponectin HDL-cholesterol 0.61 < 0.001 
HMW adiponectin LDL-cholesterol –0.40 < 0.05 
HMW adiponectin Insulin –0.54 < 0.01 
HMW adiponectin HOMA-IR –0.53 < 0.001 
MMW adiponectin BMI –0.58 < 0.001 
MMW adiponectin HDL-cholesterol 0.55 < 0.01 
MMW adiponectin Triglycerides –0.40 < 0.05 
LMW adiponectin BMI –0.36 < 0.05 
LMW adiponectin HDL-cholesterol 0.45 < 0.05 
LMW adiponectin LDL-cholesterol –0.41 < 0.05 
HMW — high molecular weight; MMW — medium molecular weight; LMW — low molecular 
weight; BMI — body mass index; HDL — high-density lipoproteins; LDL — low-density 
lipoproteins; HOMA-IR — Homeostatic Model Assessment-Insulin Resistance 
 
Table 4. Correlations of omentin in patients with multiple sclerosis (MS) 
Parameter A Parameter B R p 
Omentin Insulin  –0.47 < 0.01 
Omentin HOMA-IR –0.43 < 0.05 
HOMA-IR — Homeostatic Model Assessment-Insulin Resistance 
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Table 5. Correlation of Expanded Disability Status Scale (EDSS) in patients with multiple 
sclerosis (MS) 
Parameter A Parameter B R p 
EDSS BMI 0.36 < 0.05 
EDSS HDL-cholesterol  –0.47 < 0.01 
BMI — body mass index; HDL — high-density lipoproteins 
 
 
 
